Experimental scrutiny and project timelines : an example
Dooley, N. and Ford, S. J. and Prasad, Elke and Elliott, M. and Halbert, Gavin (2010) Experimental scrutiny and project timelines : an example. Journal of Pharmacy and Pharmacology, 62 (10). pp. 1208-1209. ISSN 0022-3573 (https://doi.org/10.1111/j.2042-7158.2010.01178.x)
Preview |
PDF.
Filename: Poster_APS_Nottingham_2010.pdf
Accepted Author Manuscript Download (555kB)| Preview |
Abstract
AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.
ORCID iDs
Dooley, N., Ford, S. J., Prasad, Elke ORCID: https://orcid.org/0000-0002-5412-9374, Elliott, M. ORCID: https://orcid.org/0000-0002-9964-5671 and Halbert, Gavin;-
-
Item type: Article ID code: 37133 Dates: DateEventOctober 2010PublishedNotes: ABSTRACTS FROM THE UK-PHARMSCI CONFERENCE, 1–3 SEPTEMBER 2010 Subjects: Medicine > Therapeutics. Pharmacology Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 26 Jan 2012 16:09 Last modified: 25 Nov 2024 01:06 URI: https://strathprints.strath.ac.uk/id/eprint/37133